Amarin reported $72.74M in Sales Revenues for its fiscal quarter ending in June of 2025.


Sales Change Date
AbbVie USD 15.42B 2.08B Jun/2025
Alnylam Pharmaceuticals USD 773.69M 179.5M Jun/2025
Amarin USD 72.74M 30.72M Jun/2025
AstraZeneca USD 14.46B 867M Jun/2025
DBV Technologies USD 1.46M 712K Jun/2025
GlaxoSmithKline GBP 7.99B 470M Jun/2025
Halozyme Therapeutics USD 206M 59M Jun/2025
Ionis Pharmaceuticals USD 452M 320M Jun/2025
Neurocrine Biosciences USD 687.5M 114.9M Jun/2025
Novartis USD 14.05B 821M Jun/2025